Myriad Genetics, Inc.

University of Utah Research Foundation

The United States of America As Represented by the Department of Health

The United States of America As Represented by the Secretary of Health

Cancer Institute

Centre De Recherche Du Chul

Other

Agridyne Technologies, Inc.

Myraid Genetics, Inc.

Mark H. Skolnick

Donna M. Shattuck-eidens

Sean V. Tavtigian

David E. Goldgar

Yoshio Miki

P. Andrew Futreal

Donna M Shattuck-Eidens

Sean V Tavtigian

Alexander Kamb

Mark H Skolnick

David E Goldgar

Roger W Wiseman

P Andrew Futreal

Jeff Swenson

Keith D Harshman

Yusuke Nakamura

Jacques Simard

Mitsuuru Emi

Francine Durocher

Timothy George Helentjaris

Suzanne R Ellenberger

Bradley D Swedlund

Charles E Hussey, Jr

Russell N Bell

Galen D Peiser

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

17q-linked breast and ovarian cancer susceptibility gene

170-linked breast and ovarian cancer susceptibility gene

17Q-linked breast and ovarian cancer susceptibility gene

Linked breast and ovarian cancer susceptibility gene

This invention provides a purified chrysanthemyl diphosphate synthase (CDS), a method for the purification of CDS from Chrysanthemum cinerariaefolium, and an amino acid sequence of the isolated CDS. Also provided is a cDNA encoding the CDS, a nucleotide sequence of the CDS gene, and a derived amino acid sequence of the encoded CDS protein. The CDS gene is useful in the enzymatic production of the natural stereospecific configuration of chrysanthemyl derivatives which are useful for the synthesis of pyrethrins, pyrethroids, derivatives thereof, as well as other classes of metabolites.

Chrysanthemyl diphosphate synthase, corresponding genes and use in

Improvements in the efficiency and sensitivity of restriction fragment length polymorphism (RFLP) detection in target sequences are realized by developing primers that are specific for nucleic acid sequences, labelling those primers with distinguishable, non-radioactive labels, such as chromophores, and applying the primers in sets such that, after amplification of the target sequence, specific sequences, in particular those of RFLPs, can be identified by virtue of the probe(s) which hybridized.

Method and device for improved restriction fragment length polymorphism

Growing community of inventors

Salt Lake City, UT, United States of America

Donna M Shattuck-Eidens